Clinical research company Atlanta Center for Medical Research (ACMR) revealed on Tuesday the appointment of Eric Riesenberg (CPA) as its chief executive officer.
Effective immediately, Riesenberg succeeds his father and the company's founder, Dr Robert Riesenberg.
Prior to the new appointment, Riesenberg has served as an advisor to ACMR's board of directors since 2001 and director of operations since 2008.
Currently, Riesenberg is a member of the board of advisors to the Metro Atlanta Chamber of Commerce and works with the Bioscience Leadership Council; a member of the American Israel Chamber of Commerce and works with the medical committee; as well as a member of the Drug Information Association (DIA) and American Society of Clinical Psychopharmacology (ASCP).
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA